Department of Clinical and Motor Neuroscience, UCL Queen Square Institute of Neurology, London (N.S.W.).
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA (S.T.C.).
Stroke. 2020 Oct;51(10):3169-3173. doi: 10.1161/STROKEAHA.120.030486. Epub 2020 Sep 21.
The repair and recovery of the brain after stroke is a field that is emerging in its preclinical science and clinical trials. However, recent large, multicenter clinical trials have been negative, and conflicting results emerge on biological targets in preclinical studies. The coalescence of negative clinical translation and confusion in preclinical studies raises the suggestion that perhaps the field of stroke recovery faces a fate similar to stroke neuroprotection, with interesting science ultimately proving difficult to translate to the clinic. This review highlights improvements in 4 areas of the stroke neural repair field that should reorient the field toward successful clinical translation: improvements in rodent genetic models of stroke recovery, consideration of the biological target in stroke recovery, stratification in clinical trials, and the use of appropriate clinical trial end points.
中风后的大脑修复和恢复是一个处于临床前科学和临床试验新兴阶段的领域。然而,最近的大型多中心临床试验结果为阴性,而且临床前研究中的生物靶点也出现了相互矛盾的结果。负面的临床转化和临床前研究中的困惑结果表明,中风恢复领域可能面临与中风神经保护相似的命运,有趣的科学最终难以转化为临床实践。本综述强调了中风神经修复领域的 4 个方面的改进,这将使该领域朝着成功的临床转化方向发展:中风恢复的啮齿动物遗传模型的改进、中风恢复的生物学靶点的考虑、临床试验的分层以及适当的临床试验终点的使用。